Lund­beck CEO bags $20M bonus jump­ing ship for Te­va helm

⇨ Lund­beck CEO Kåre Schultz land­ed the CEO post at Te­va $TE­VA, win­ning a $20 mil­lion sign­ing bonus as he tack­les one of the biggest re­or­ga­ni­za­tions now un­der­way in the in­dus­try. The an­nounce­ment will fi­nal­ly lay to rest long bub­bling ru­mors about who will helm the Is­raeli com­pa­ny.

⇨ An­oth­er se­nior As­traZeneca R&D ex­ec has jumped ship. San­jay Jari­wala is mov­ing on to Bio­gen, where he will be the new se­nior vice pres­i­dent, world­wide med­ical, re­port­ing to Al San­drock.

⇨ Roivant Sci­ences is ex­pand­ing its man­age­ment team, with Allen Wax­man join­ing the com­pa­ny as gen­er­al coun­sel, Matthew Gline be­ing pro­mot­ed to chief fi­nan­cial of­fi­cer and Pa­van Cheru­vu named chief peo­ple of­fi­cer.

⇨ Amarin Cor­po­ra­tion $AM­RN an­nounced that Mark W. Saly­er has joined the com­pa­ny as chief com­mer­cial of­fi­cer. In this new­ly cre­at­ed po­si­tion, Saly­er will work to “build on the com­pa­ny’s re­cent rev­enue growth and lead fu­ture glob­al com­mer­cial ex­pan­sion plans and ex­e­cu­tion.”

⇨ Ax­cel­la Health re­cruit­ed Manu Chakravarthy as its new CMO and se­nior vice pres­i­dent of clin­i­cal de­vel­op­ment.

⇨ Er­ic Topol has re­signed from the board of Myokar­dia $MYOK. The SEC fil­ing not­ed that he isn’t leav­ing due to any dis­agree­ment and that Topol will stay on as an ad­vis­er.

⇨ Celldex Ther­a­peu­tics $CLDX says that Thomas Davis has re­signed as ex­ec­u­tive vice pres­i­dent and chief med­ical of­fi­cer, ef­fec­tive at the end of this month.

⇨ Mannkind $MNKD has filed an 8-K not­ing the res­ig­na­tion of CMO Ray­mond Ur­ban­s­ki.

⇨ Karyopharm Ther­a­peu­tics $KP­TI  has tapped Michael Falvey as ex­ec­u­tive vice pres­i­dent, CFO and trea­sur­er. The com­pa­ny al­so an­nounced that Jatin Shah has as­sumed the role of vice pres­i­dent, clin­i­cal strat­e­gy, and Joan Wood has as­sumed the role of chief hu­man re­sources Of­fi­cer.

⇨ PDL Bio­Phar­ma $PDLI  has ap­point­ed Do­minique P. Mon­net as pres­i­dent. He brings more than 30 years of in­ter­na­tion­al busi­ness ex­pe­ri­ence in the biotech­nol­o­gy/phar­ma­ceu­ti­cal in­dus­try.

⇨ The CNS spe­cial­ist Min­er­va Neu­ro­sciences $NERV an­nounced the ap­point­ment of Jay Saoud as se­nior vice pres­i­dent, head of re­search and de­vel­op­ment.

⇨ Af­fimed $AFMD has re­cruit­ed Wolf­gang Fis­ch­er as chief op­er­at­ing of­fi­cer. He’s join­ing the com­pa­ny from San­doz, the big No­var­tis unit.

⇨ Hori­zon Phar­ma plc has named Iri­na Kon­stan­ti­novsky, ex­ec­u­tive vice pres­i­dent and chief hu­man re­sources of­fi­cer. Kon­stan­ti­novsky joined Hori­zon from Bax­ter In­ter­na­tion­al, where she was vice pres­i­dent of glob­al tal­ent. Pri­or to Bax­ter, Kon­stan­ti­novsky spent 15 years in se­nior part­ner and di­rec­tor roles at Tow­ers Wat­son (cur­rent­ly Willis Tow­ers Wat­son), a glob­al hu­man re­sources con­sult­ing firm.

Late Fri­day ap­proval; Trio of biotechs wind down; Stem cell pi­o­neer finds new fron­tier; Biotech icon to re­tire; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

I hope your weekend is off to a nice start, wherever you are reading this email. As for me, I’m trying to catch the tail of the Lunar New Year festivities.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.

Pfiz­er lays off em­ploy­ees at Cal­i­for­nia and Con­necti­cut sites

Pfizer has laid off employees at its La Jolla, CA, and Groton, CT sites, according to multiple LinkedIn posts from former employees.

The Big Pharma confirmed to Endpoints News it has let go of some employees, but a spokesperson declined to specify how many workers were impacted and the exact locations affected. Earlier this month, the drug developer had confirmed to Endpoints it was sharpening its focus and doing away with some early research on areas such as rare disease, oncology and gene therapies.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Jake Van Naarden, Loxo@Lilly CEO

Lil­ly en­ters ripe BTK field with quick FDA nod in man­tle cell lym­phoma

Eli Lilly has succeeded in its attempt to get the first non-covalent version of Bruton’s tyrosine kinase, or BTK, inhibitors to market, pushing it past rival Merck.

The FDA gave an accelerated nod to Lilly’s daily oral med, to be sold as Jaypirca, for patients with relapsed or refractory mantle cell lymphoma.

The agency’s green light, disclosed by the Indianapolis Big Pharma on Friday afternoon, catapults Lilly into a field dominated by covalent BTK inhibitors, which includes AbbVie and Johnson & Johnson’s Imbruvica, AstraZeneca’s Calquence and BeiGene’s Brukinsa.

Filip Dubovsky, Novavax CMO

No­vavax gets ready to take an­oth­er shot at Covid vac­cine mar­ket with next sea­son plans

While mRNA took center stage at yesterday’s FDA vaccine advisory committee meeting, Novavax announced its plans to deliver an updated protein-based vaccine based on new guidance.

Vaccines and Related Biological Products Advisory Committee (VRBPAC) members voted unanimously in favor of “harmonizing” Covid vaccine compositions, meaning all future vaccine recipients would receive a bivalent vaccine, regardless of whether they’ve gotten their primary series.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.

Eliot Forster, F-star CEO (Rachel Kiki for Endpoints News)

F-star gets down to the wire with $161M sale to Chi­nese buy­er as na­tion­al se­cu­ri­ty con­cerns linger

With the clock ticking on F-star Therapeutics’ takeover by a Chinese buyer, the companies are still scrambling to remove a hold on the deal from the US government’s Committee on Foreign Investment in the United States.

F-star and invoX Pharma said they are “actively negotiating” with CFIUS “about the terms of a mitigation agreement to address CFIUS’s concerns regarding potential national security risks posed by the transaction.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.

Ex­clu­sive: Cell ther­a­py biotech brings on Loxo vet amid glob­al ex­pan­sion plans; Re­tire­ment beck­ons for Vir's George Scan­gos

Bree Harlin, who used to be director of clinical operations at Loxo Oncology, now Loxo@Lilly, is now in the C-suite for the first time.

Harlin started at TC BioPharm on Wednesday as chief clinical officer, the biotech announced Friday — but her journey starts more than 20 years before then. After graduating from college, she moved to Boston, working in academia at some of the Harvard teaching hospitals in endocrinology and CNS.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.

CBER Director Peter Marks (Susan Walsh/AP Images)

FDA ad­vi­so­ry com­mit­tee votes unan­i­mous­ly in fa­vor of bi­va­lent Covid shots re­plac­ing pri­ma­ry se­ries

The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously in favor of “harmonizing” Covid vaccine compositions, meaning all current vaccine recipients would receive a bivalent vaccine, regardless of whether they’ve gotten their primary series.

The vote marks an effort to clear up confusion around varying formulations and dosing schedules for current primary series and booster vaccines, as well as “get closer to the strains that are circulating,” according to committee member Paul Offit, professor of pediatrics at the Children’s Hospital of Philadelphia.

Rodney Rietze, iVexSol CEO

Bris­tol My­ers, Charles Riv­er join Se­ries A fund­ing for iVex­Sol

Massachusetts-based iVexSol has secured funding to the tune of $23.8 million in its latest Series A round. The new investors include Bristol Myers Squibb, manufacturer Charles River Laboratories and Asahi Kasei Medical.

iVexSol is a manufacturer of lentiviral vectors (LVV), used in making gene therapies, and this latest round of fundraising brings its total Series A total over $39 million, which will be used to recruit more employees and bolster its technology.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.

John Rim, Samsung Biologics CEO (Samsung/PR Newswire)

Sam­sung Bi­o­log­ics spells out ex­pan­sion plans in South Ko­rea and US

The CDMO arm of one of South Korea’s largest conglomerates has posted its year-end results and plans for 2023, which include new construction.

Samsung Biologics netted north of KRW 3 trillion ($2.4 billion) in 2022 revenue and an operating profit of KRW 983.6 billion ($799 million), which the company touted on Friday as “record-high earnings.” The revenue boost was 55% compared to 2021.